- $33.72m
- -$7.85m
- $8.98m
InspireMD Inc reports results for the quarter ended December 31 - Earnings Summary
InspireMD Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: InspireMD And NAMSA To Partner On CGuardians II Pivotal Clinical Trial Of The CGuard Prime 80 Cm Carotid Stent System For Use In TCAR Procedures
Brief: InspireMD Announces Appointment Of Accomplished Medical Technology Executive Scott R. Ward To Its Board Of Directors
InspireMD Inc reports results for the quarter - Earnings Summary
Brief: Inspiremd Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
InspireMD Inc expected to post a loss of 20 cents a share - Earnings Preview
InspireMD Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: InspireMD Announces Establishment Of Global Headquarters In Miami
Brief: InspireMD Announces Approval Of Application For Pivotal Study Of The CGuard Prime 80Cm Carotid Stent System
Brief: Inspiremd Announces Submission Of Premarket Approval Application To FDA Seeking U.S. Regulatory Approval Of The Cguard™ Prime Carotid Stent System
InspireMD Inc reports results for the quarter ended in June - Earnings Summary
InspireMD Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Inspiremd Files Prospectus Supplement To Offer, Sell Common Stock Of Up To $17 Million From Time To Time Under Equity Distribution Deal With Piper Sandler
InspireMD Inc reports results for the quarter ended in January - Earnings Summary
InspireMD Inc expected to post a loss of 15 cents a share - Earnings Preview
InspireMD Inc reports results for the quarter ended in December - Earnings Summary
Brief: InspireMD Q4 revenue USD 1.761 million
Brief: InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System